Core Insights - Algeria is advancing its pharmaceutical sovereignty strategy, achieving significant progress in key areas such as insulin, anticancer drugs, and hormone medications, while gradually exporting domestically produced medicines to multiple African countries [1] Industry Development - The Algerian Ministry of Pharmaceutical Industry is focusing on expanding local production capacity and attracting global pharmaceutical companies' technologies, with health sovereignty as a core aspect of its industrial policy [1] - Algeria has established strategic partnerships with several leading international laboratories to acquire the latest innovations in pharmaceutical technology [1] Production Capacity - The country has approved 100 new pharmaceutical production projects, which will significantly enhance local production capabilities and improve the quality of domestically produced medicines [1] - Algeria currently has over 230 pharmaceutical companies and 780 production lines, indicating a robust growth in the pharmaceutical sector and reflecting the country's ambition to become a key pharmaceutical hub in Africa and the Mediterranean region [1]

Group 1 - The core point of the news is that President Trump has threatened pharmaceutical companies with a potential 200% tariff on imported drugs, but the market has reacted calmly due to the provided grace period for companies to adjust [1][2] - The grace period of "one to one and a half years" allows pharmaceutical companies ample time to stockpile and shift production, significantly reducing investor concerns [1][2] - Major pharmaceutical companies are already taking proactive measures, such as stockpiling drugs and increasing domestic production investments, indicating that industry confidence remains intact despite tariff threats [1][3] Group 2 - The grace period could extend until 2027, and companies may further extend their response time to 2028 through stockpiling, providing a strategic planning window for long-term adjustments [2] - The pharmaceutical industry is accelerating stockpiling, with hormone drug exports from Ireland to the U.S. valued at $36 billion this year, more than double last year's total [3] - Companies like Eli Lilly are investing heavily in U.S. manufacturing, with a $27 billion expansion plan, and tax incentives from Trump's "Big Beautiful Plan" are helping to mitigate the costs of establishing new facilities [3]

Core Viewpoint - The case of a young patient developing cataracts due to long-term use of steroid medications highlights the potential risks associated with such treatments, particularly in dermatological conditions [1][3]. Group 1: Patient Case Summary - A 22-year-old patient, referred to as Xiao Zhang, experienced a significant decline in vision, ultimately diagnosed with cataracts [1][3]. - The cataract was attributed to over a year of steroid and biological agent use for treating neurodermatitis, which led to the development of steroid-induced cataracts [3]. Group 2: Medical Insights - Steroid-induced cataracts are a common type of cataract resulting from prolonged use of steroid medications, either orally or topically [3]. - The exact mechanism of steroid-induced cataracts is not fully understood, but it may involve glucocorticoid receptor mediation and abnormal cell adhesion [3]. - Patients using steroids for extended periods may face progressive eye-related side effects, necessitating regular eye examinations [4]. Group 3: Treatment and Recovery - The medical team proposed a surgical solution involving femtosecond laser-assisted implantation of a trifocal intraocular lens, which successfully restored the patient's vision to 1.0 within a day post-surgery [3].